Abstract:Introduction: Peripheral arterial disease (PAD) is caused by atherosclerosis. PAD is a common disease that affects 12% of the adult population and causes significant morbidity and mortality. The existing treatments for PAD, including pharmacological, interventional and surgical procedures, are not sufficient and many patients are opt for limb amputation. Therapeutic angiogenesis using angiogenic factors has been considered to be a potential treatment option for PAD patients. Hypothesis: In this study, we assessed the potential of a new angiogenic factor AGGF1 for therapeutic angiogenesis in a critical limb ischemia model in mice for PAD. Methods and Results: We generated a unilateral hindlimb ischemia model in mice by ligation of the right common iliac artery and femoral artery. Ischemic mice with intrasmuscular administration of DNA for an expression plasmid for human AGGF1 ( AGGF1 group) resulted in increased expression of both AGGF1 mRNA and protein after the administration compared with control mice of hindlimb ischemia with injection of the empty vector (control group). The blood flow in ischemic hindlimbs was significantly increased in the AGGF1 group compared to control mice at time points of 7, 14, and 28 days after DNA administration. Four weeks after the injection of DNA, the blood flow was approximately 2.19 fold higher in AGGF1 group than that in control. With the increased blood flow in the AGGF1 group, ambulatory impairement were inhibited compared with the control group. Increased AGGF1 expression decreased necrosis in muscle tissues injected with AGGF1 DNA compared with the control tissue injected with the empty vector. CD31-positive capillary vessel density was significantly higher in AGGF1 -injected limbs than in empty vector-injected limbs. Conclusions: These data establish that plasmid DNA-based gene transfer of AGGF1 into mouse skeletal muscles is efficient in increase the expression levels of AGGF1 mRNA and protein. Increased AGGF1 expression increases blood flow by increasing density of CD31-positive vessels and by decreasing necrosis in muscle tissues. These findings suggest that AGGF1 may be used as a candidate therapeutic agent for therapeutic angiogenesis to treat PAD.

Targeting AGGF1 (angiogenic factor with G patch and FHA domains 1) for Blocking Neointimal Formation After Vascular Injury.

Angiogenic factor AGGF1 blocks neointimal formation after vascular injury via interaction with integrin α7 on vascular smooth muscle cells

Angiogenic Factor AGGF1 Promotes Therapeutic Angiogenesis in a Mouse Limb Ischemia Model

Abstract 216: Angiogenic Factor AGGF1 Promotes Therapeutic Angiogenesis in a Mouse Limb Ischemia Model for Peripheral Arterial Disease

AGGF1 therapy inhibits thoracic aortic aneurysms by enhancing integrin α7-mediated inhibition of TGF-β1 maturation and ERK1/2 signaling

AGGF1 therapy inhibits thoracic aortic aneurysms by enhancing integrin a7mediated inhibition of TGF-beta 1 maturation and ERK1/2 signaling

Receptor and Molecular Mechanism of AGGF1 Signaling in Endothelial Cell Functions and Angiogenesis

Angiogenic Factor With G Patch And Fha Domains 1 Is A Novel Regulator Of Vascular Injury

Myeloid-derived growth factor suppresses VSMC dedifferentiation and attenuates postinjury neointimal formation in rats by activating S1PR2 and its downstream signaling

Angiogenic Factor AGGF1 Activates Autophagy with an Essential Role in Therapeutic Angiogenesis for Heart Disease.

Inhibition of Neointimal Hyperplasia in the Rat Carotid Artery Injury Model by A Hmgb1 Inhibitor

AGGF1 is a novel anti-inflammatory factor associated with TNF-α-induced endothelial activation.

Non-Mitogenic Fibroblast Growth Factor 1 Enhanced Angiogenesis Following Ischemic Stroke by Regulating the Sphingosine-1-Phosphate 1 Pathway

Vascular Adventitial Fibroblasts-Derived FGF10 Promotes Vascular Smooth Muscle Cells Proliferation and Migration in Vitro and the Neointima Formation in Vivo

Perivascular Gene Transfer of Dominant-Negative N19RhoA Attenuates Neointimal Formation Via Inhibition of TGF-β1-Smad2 Signaling in Rats after Carotid Artery Balloon Injury

Apigenin attenuates neointima formation via suppression of vascular smooth muscle cell phenotypic transformation.

Gene therapy with human vascular endothelial growth factor in prevention of restenosis after angioplasty

Inhibition of Angiopoietin-2 Production by Myofibrocytes Inhibits Neointimal Hyperplasia after Endoluminal Injury in Mice

CKLF1 aggravates neointimal hyperplasia by inhibiting apoptosis of vascular smooth muscle cells through PI3K/AKT/NF-κB signaling.

Intramuscular gene transfer of CGRP inhibits neointimal hyperplasia after balloon injury in the rat abdominal aorta.

Autophagy is required for the promoting effect of angiogenic factor with G patch domain and forkhead-associated domain 1 (AGGF1) in retinal angiogenesis